Topelia Australia launches US$25M Series A call for COVID-19 ATT Ziverdox
![Image](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi5TzKfBVofZQJMCtI6Dig-YW2r546jbnFWYCjto51xMZ7ZJ9DTCi3LP3_zj5XNWJSf1H4fCzX7EUNG-sd0SHii_X4YGUVKDG1UYc5TfrAMiXknUAJyqrydHfg9NegjFc2MGzmkn0f39-YY/w640-h376/Screenshot+2021-12-01+at+3.49.23+AM.png)
SYDNEY, Oct 14, 2021 - (ACN Newswire) - Topelia Australia, a biotech company established to commercialise a novel ATT treatment for Australians in quarantine, has launched an investment program designed to keep the invention Australian owned - while rolling out treatment to the world. - Topelia announces US$25 mil Series A capital raise to fund manufacture and clinical trials of the COVID-19 Antiviral Triple Therapy (ATT). - Topelia has secured exclusive global patent rights to COVID-19 Antiviral Triple Therapy from Prof Thomas Borody. - Borody's track record includes effective treatment for Peptic Ulcers & Crohn's Disease, recolonisation of bowel microbiome, and 3 FDA approved drugs on the market. - Based on current research, the ATT provides an inexpensive and medically efficacious treatment for the prevention and early treatment of COVID-19. The company is raising USD$25 million from investors in Australia, Asia and USA. The company said: "Topelia proposes to offer